Xeltis BV announced encouraging preliminary safety and patency data from ongoing clinical trials of Xabg, its bioengineered coronary artery bypass conduit. The implant uses supramolecular chemistry to create nanofibers that support gradual replacement by the patient’s own tissue, aiming to restore natural vascular function. Trials in Europe and South America have demonstrated promising outcomes in patients with multi-vessel atherosclerotic coronary artery disease. This innovation represents progress in regenerative cardiovascular medicine and artificial tissue engineering.